Monthly ArchivesNovember 2020

FDA Orphan Drug Designation for EXE-346 Live Biotherapeutic standard

November 12, 2020 (Rockville, Maryland): ExeGi Pharma LLC, a company focused on developing live biotherapeutic (“LBP”) drugs and probiotics, announced today that its biologic drug candidate, EXE-346, has received an orphan drug designation from the U.S. Food and Drug Administration (FDA) for the prevention of disease relapse in pouchitis. This designation grants certain benefits to drugs and biological products intended to treat diseases which affect less than 200,000 patients in the U.S. EXE-346 is an LBP which contains a fixed-proportion of 8 strains of live probiotic bacteria which are intended for oral administration. Pouchitis is a condition which impacts patients who have had a surgical procedure to remove their colon. The surgery, called a pouch anastomosis, creates an intestinal “J-Pouch” ...

Continue Reading

This is a unique website which will require a more modern browser to work!

Please upgrade today!